Show simple item record

dc.contributor.authorMuecksch, Frauke
dc.contributor.authorHou, Shurong
dc.contributor.authorSchiffer, Celia A.
dc.contributor.authorNussenzweig, Michel C.
dc.contributor.authorBjorkman, Pamela J.
dc.contributor.authorHatziioannou, Theodora
dc.contributor.authorBieniasz, Paul D.
dc.date2022-08-11T08:08:10.000
dc.date.accessioned2022-08-23T15:45:16Z
dc.date.available2022-08-23T15:45:16Z
dc.date.issued2021-08-10
dc.date.submitted2021-08-27
dc.identifier.citation<p>Muecksch F, Weisblum Y, Barnes CO, Schmidt F, Schaefer-Babajew D, Wang Z, C Lorenzi JC, Flyak AI, DeLaitsch AT, Huey-Tubman KE, Hou S, Schiffer CA, Gaebler C, Da Silva J, Poston D, Finkin S, Cho A, Cipolla M, Oliveira TY, Millard KG, Ramos V, Gazumyan A, Rutkowska M, Caskey M, Nussenzweig MC, Bjorkman PJ, Hatziioannou T, Bieniasz PD. Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity. 2021 Aug 10;54(8):1853-1868.e7. doi: 10.1016/j.immuni.2021.07.008. Epub 2021 Jul 30. PMID: 34331873; PMCID: PMC8323339. <a href="https://doi.org/10.1016/j.immuni.2021.07.008">Link to article on publisher's site</a></p>
dc.identifier.issn1074-7613 (Linking)
dc.identifier.doi10.1016/j.immuni.2021.07.008
dc.identifier.pmid34331873
dc.identifier.urihttp://hdl.handle.net/20.500.14038/27489
dc.description<p>This article is based on a previously available preprint on <a href="https://doi.org/10.1101/2021.03.07.434227" target="_blank" title="view preprint in biorxiv">bioRxiv</a> that is also available in <a href="https://escholarship.umassmed.edu/faculty_pubs/1925/" target="_blank" title="view preprint in eScholarship@UMMS">eScholarship@UMMS</a>.</p> Full author list omitted for brevity. For the full list of authors, see article.
dc.description.abstractAntibodies elicited by infection accumulate somatic mutations in germinal centers that can increase affinity for cognate antigens. We analyzed 6 independent groups of clonally related severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) Spike receptor-binding domain (RBD)-specific antibodies from 5 individuals shortly after infection and later in convalescence to determine the impact of maturation over months. In addition to increased affinity and neutralization potency, antibody evolution changed the mutational pathways for the acquisition of viral resistance and restricted neutralization escape options. For some antibodies, maturation imposed a requirement for multiple substitutions to enable escape. For certain antibodies, affinity maturation enabled the neutralization of circulating SARS-CoV-2 variants of concern and heterologous sarbecoviruses. Antibody-antigen structures revealed that these properties resulted from substitutions that allowed additional variability at the interface with the RBD. These findings suggest that increasing antibody diversity through prolonged or repeated antigen exposure may improve protection against diversifying SARS-CoV-2 populations, and perhaps against other pandemic threat coronaviruses.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=34331873&dopt=Abstract">Link to Article in PubMed</a></p>
dc.rightsCopyright 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectSARS-CoV-2
dc.subjectantibodies
dc.subjectneutralization
dc.subjectAmino Acids, Peptides, and Proteins
dc.subjectImmunology of Infectious Disease
dc.subjectMicrobiology
dc.subjectVirology
dc.subjectVirus Diseases
dc.titleAffinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations
dc.typeJournal Article
dc.source.journaltitleImmunity
dc.source.volume54
dc.source.issue8
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1296&amp;context=covid19&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/covid19/291
dc.identifier.contextkey24527833
refterms.dateFOA2022-08-23T15:45:16Z
html.description.abstract<p>Antibodies elicited by infection accumulate somatic mutations in germinal centers that can increase affinity for cognate antigens. We analyzed 6 independent groups of clonally related severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) Spike receptor-binding domain (RBD)-specific antibodies from 5 individuals shortly after infection and later in convalescence to determine the impact of maturation over months. In addition to increased affinity and neutralization potency, antibody evolution changed the mutational pathways for the acquisition of viral resistance and restricted neutralization escape options. For some antibodies, maturation imposed a requirement for multiple substitutions to enable escape. For certain antibodies, affinity maturation enabled the neutralization of circulating SARS-CoV-2 variants of concern and heterologous sarbecoviruses. Antibody-antigen structures revealed that these properties resulted from substitutions that allowed additional variability at the interface with the RBD. These findings suggest that increasing antibody diversity through prolonged or repeated antigen exposure may improve protection against diversifying SARS-CoV-2 populations, and perhaps against other pandemic threat coronaviruses.</p>
dc.identifier.submissionpathcovid19/291
dc.contributor.departmentSchiffer Lab
dc.contributor.departmentDepartment of Biochemistry and Molecular Pharmacology
dc.source.pages1853-1868.e7


Files in this item

Thumbnail
Name:
Publisher version
Thumbnail
Name:
1_s2.0_S1074761321002946_main.pdf
Size:
4.935Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Copyright 2021 The Authors. Published by Elsevier Inc.  This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Except where otherwise noted, this item's license is described as Copyright 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).